Verastem Inc. (VSTM)

5.69 -0.16 (-2.735%)

IEX Real-Time Price

October 19, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 5.85

Price Open 5.78

Volume: 2.29M

Avg Volume: 3.88M

Market Cap: 419.5M

P/E Ratio -3.25

52 Wk Range 2.77-10.35



VSTM Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-09-28
72.03M
14.62M
3.74
20.30%

2018-09-14
72.03M
8.07M
3.29
11.20%

2018-08-31
72.03M
6.59M
2.89
9.15%

2018-08-15
72.03M
6.02M
3.31
8.35%




VSTM Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-08-08
Q2 2018
N/A
-0.35 (6)
-0.30
0.05

2018-05-09
Q1 2018
N/A
-0.41 (4)
0.00
0.00

2018-05-03
Q1 2018
N/A
-0.41 (4)
-0.41
0.00

2018-03-22
Q4 2017
N/A
-0.43 (4)
0.00
0.00

News

Verastem Oncology Announces Executive Leadership Appointments and Changes (2018-10-18 16:05 Business Wire)

Gina Consylman Joining Board of Directors Hagop Youssoufian, MSc, MD Transitioning to Head of Medical Strategy Kirk Taylor, MD, Appointed Senior Vice President, Medical Affairs Strategy and Operations Verastem, Inc. (Nasdaq: VSTM) (Verastem Oncology or the Company), focused …

 


Statistics

Shares Outstanding: 73.73M

Top 15 Institution Percent: 46.20

Price To Sales: 43.13

Price To Book: 3.40

Revenue: N/A

Gross Profit: N/A

Cash: 60.26M

Debt: N/A

Return On Assets: -68.82

Return On Equity: -92.27

Profit Margin: N/A

Price History

Beta: 3.09

50-day Moving Avg: 7.99

200-day Moving Avg: 5.64

YTD Change: 77.26

5-day Change: -4.29

1-month Change: -35.05

3-month Change: -29.49

6-month Change: 37.44

1-year Change: 45.90

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Verastem Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.verastem.com

Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.